In the rapidly evolving landscape of healthcare, JB Pharma, a subsidiary of JB Holdings, is making significant strides in revolutionising patient care. Partnering with Zion Medical BV, an Israeli biopharmaceutical company, JB Pharma is at the cutting edge of research and development in the treatment of AIDS, Cancer, and other immune deficiency diseases.
Pioneering Research and Development
JB Pharma’s collaboration with Zion Medical has led to groundbreaking research, particularly in the development of Gammora, a peptide-based drug aimed at eradicating HIV-infected human cultured cells and cancer cells. This research has been conducted at esteemed institutions like the Hebrew University and Kaplan HIV Medical Centre in Israel, demonstrating its effectiveness and potential for transforming healthcare.
A Focus on Peptide-Based Treatments
The experimental drug Gammora contains peptides derived from the HIV virus that promote infected cells into self-induced death (apoptosis). This approach is unique and offers a new avenue for treating not just HIV but also various forms of cancer. The peptides, when used in conjunction with harmless Lenti-Virus-Particles, disrupt the infected cells’ chromosomes, forcing them into apoptosis. This process eradicates the infected cells without harming normal cells, offering a potentially curative treatment for both illnesses.
Achievements and Milestones
JB Pharma and Zion Medical have achieved several key milestones in their research:
- Demonstrated the effectiveness of the peptides on blood drawn from HIV patients.
- Demonstrated the activity of the peptides in lung, pancreatic, colon, and breast cancer cells.
- Conducted successful trials on HIV-infected mice cultured cells.
Ethical and Responsible Research
JB Pharma is committed to conducting its research under the highest ethical standards. All trials and studies are carried out with full transparency and in accordance with international research guidelines.
The Future of JB Pharma
As JB Pharma continues to forge ahead in its quest for medical advancements, its focus remains on revolutionising patient care. With several more studies and clinical trials in the pipeline, the subsidiary is well on its way to making a significant impact in the healthcare sector, both in South Africa and globally.
In a world where healthcare challenges are ever-present, JB Pharma’s innovative approaches offer a beacon of hope. The company is not just contributing to medical science; it’s shaping the future of patient care.
If you have any questions about our subsidiaries, including JB Minerals, JB Oil, JB Pharma, JB Property Fund, and JB Finance, we invite you to contact us. Our team is on hand to discuss how our services can support your needs and contribute to the growth of your business.
